BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.3% ·
share flow -3.1% ·
net new positions -5.6%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 26.23K | $1.72M | n/a | −1 |
| Q2 2026 | 132 | +3 | 120.71M | $8.69B | +10 | −8 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | n/a | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | n/a |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | n/a | −1 |
| Q2 2024 | 13 | n/a | 36.42M | $922.50M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 18.56M | -15.9% | $801.22M | 2.3% | ▼ Trim | 5 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 16.48M | n/a | $711.82M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (passive) | 14.26M | n/a | $615.72M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 4 | State Street Global Advisors ✦ (passive) | 5.90M | +2.6% | $254.62M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 3.68M | +5.1% | $158.99M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.34M | +177.4% | $101.00M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 2.08M | +2403.0% | $89.87M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 2.03M | n/a | $87.54M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | Norges Bank ✦ (passive) | 1.96M | +57.2% | $84.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 961.22K | -17.5% | $41.51M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 620.46K | +158.6% | $26.79M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | PRIMECAP Management ✦ | 588.71K | -35.5% | $25.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Marshall Wace ✦ | 422.71K | +0.2% | $18.25M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Citadel Advisors ✦ | 332.32K | -88.7% | $14.35M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 15 | Adage Capital Partners ✦ | 301.36K | -41.7% | $13.01M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 245.95K | New | $10.62M | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 157.81K | +17.5% | $6.81M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 18 | Wellington Management ✦ | 56.67K | -5.6% | $2.45M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $10.62M | 0.0% |
Exited
| Duquesne Family Office | $15.14M | was 0.5% |
| Point72 Asset Management | $6.87M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 15.30K shares, $1,136 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.28K sh · $88,980
Officer, Director · 8.72K sh · $601,868
Officer, Director · 1.80K sh · $152,436
Officer, Director · 100 sh · $8,565
Officer, Director · 8.10K sh · $679,256
Officer, Director · 1.90K sh · $154,184
Officer, Director · 17.28K sh · $1.42M
Officer, Director · 14.60K sh · $1.21M
Officer, Director · 1.20K sh · $100,444
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
4.2% of class · View original SEC filing ↗
5.0% of class · View original SEC filing ↗